ZEJULA (niraparib) logo

Product menu

Image of fictitious patient

Quality of life

In PRIMA, ZEJULA (niraparib) preserved QoL for over 30 treatment cycles for women living with advanced ovarian cancer comparable to placebo

What if your patients could maintain their QoL for over 30 cycles?

FOSI QoL over 30 cycles of maintenance therapy with ZEJULA vs placebo1

A graph showing health-related QoL/patient-reported outcomes of Zejula (niraparib) vs placebo

FOSI QoL domains included:

Mobility

Self-care

Anxiety/depression

Pain/discomfort

Usual activities

WHAT ABOUT ZEJULA EFFICACY?

Find out more

ZEJULA dosing

ZEJULA safety profile

PRIME vs PRIMA

ZEJULA is indicated

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Abbreviations

FIGO, Federation of Gynaecology and Obstetrics; FOSI, Functional Assessment of Cancer Therapy-Ovarian Symptoms Index; QoL, quality of life; SE, standard error.

References

  1. González-Martín A, et al. N Engl J Med. 2019;381(25):2391–2402.
  2. FACIT.org. Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index – 8-item version. Available at: https://www.facit.org/measures/FOSI (accessed September 2022).

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2023 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

June 2023 | PM-GB-NRP-WCNT-220020 (V1.0)